

## Supporting Information

### **A novel spirocyclic triterpenoid and a new taraxerane triterpenoid from**

#### ***Teucrium viscidum***

Zheng-Yu Li,<sup>a</sup> Feng-Ming Qi,<sup>b</sup> De-Juan Zhi,<sup>a</sup> Qiao-Ling Hu,<sup>a</sup> Ying-Hong Liu,<sup>a</sup> Zhan-Xin Zhang\*<sup>a</sup> and Dong-Qing Fei\*<sup>a</sup>

<sup>a</sup> *School of Pharmacy, Lanzhou University, Lanzhou 730000, People's Republic of China. E-mail: [zhangzhx@lzu.edu.cn](mailto:zhangzhx@lzu.edu.cn) (Z.-X. Zhang); [feidq@lzu.edu.cn](mailto:feidq@lzu.edu.cn) (D.-Q. Fei); Fax: +86 931 8915686; Tel: +86 931 8915686*

<sup>b</sup> *State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, People's Republic of China*

## Supporting Information Contents

### Experimental section

**Fig. 1S**  $^1\text{H}$  NMR (400MHz,  $\text{CDCl}_3$ ) of compound **1**

**Fig. 2S**  $^{13}\text{C}$  NMR and DEPT135 (100MHz,  $\text{CDCl}_3$ ) of compound **1**

**Fig. 3S**  $^1\text{H}$ - $^1\text{H}$  COSY spectrum of compound **1**

**Fig. 4S** HSQC spectrum of compound **1**

**Fig. 5S** HMBC spectrum of compound **1**

**Fig. 6S** NOESY spectrum of compound **1**

**Fig. 7S** HR-ESI-MS spectrum of compound **1**

**Fig. 8S** IR spectrum of compound **1**

**Fig. 9S**  $^1\text{H}$  NMR (400MHz,  $\text{C}_5\text{D}_5\text{N}$ ) of compound **2**

**Fig. 10S**  $^{13}\text{C}$  NMR and DEPT135 (100MHz,  $\text{C}_5\text{D}_5\text{N}$ ) of compound **2**

**Fig. 11S**  $^1\text{H}$ - $^1\text{H}$  COSY spectrum of compound **2**

**Fig. 12S** HSQC spectrum of compound **2**

**Fig. 13S** HMBC spectrum of compound **2**

**Fig. 14S** NOESY spectrum of compound **2**

**Fig. 15S** HR-ESI-MS spectrum of compound **2**

**Fig. 16S** IR spectrum of compound **2**

## Experimental section

**General Experimental Procedures:** Melting points were determined on an X-4 digital display micro-melting point apparatus which are uncorrected. Optical rotations were measured on a Perkin Elmer 341 polarimeter. IR spectra were taken on a Nicolet NEXUS 670 FT-IR spectrometer. NMR spectra were recorded on a Bruker AVANCE III-400 NMR spectrometer. HR-ESI-MS data were recorded on a Thermo LTQ Orbitrap Elite mass spectrometer. The X-ray crystallographic data were collected on an Agilent Technologies SuperNova, Dual source, EOS CCD with mirror optics using graphite monochromated Cu-K $\alpha$  radiation. Silica gel (200-300 mesh) used for column chromatography, and silica gel GF<sub>254</sub> used for TLC were both supplied by the Qingdao Marine Chemical Factory, Qingdao, China.

**Plant Material:** The whole plants of *Teucrium viscidum* were purchased from Hebei Anguo Medicine Market in Anguo County, Hebei Province, China, in August, 2014 and identified by Dr. Jian-Yin Li, a doctor at school of Pharmacy, Lanzhou University. A voucher specimen (No. 20140821TV) is deposited in the school of Pharmacy, Lanzhou University.

**Extraction and Isolation:** The dried whole plants of *Teucrium viscidum* (20 kg) were percolated four times (each one week) with 95% EtOH at room temperature to give 2520 g crude extract. After removal of organic solvents, the extract was suspended in H<sub>2</sub>O (1.5L) and extracted with EtOAc (3 $\times$ 1.5L) and *n*-BuOH (3 $\times$ 1.5L). The EtOAc fraction (852 g) was chromatographed on a silica gel column with a stepwise gradient of petroleum ether-acetone (40:1-1:1) to give six major fractions (A-F). The fraction A (70g) was subjected to silica gel column chromatograph (CC) and eluted with petroleum ether-acetone successively to give Fr.A1-Fr.A3. The Fr.A1 (13.6 g) was separated by silica gel CC (petroleum ether/acetone, 20:1-10:1) to afford three fractions. The Fr.A1.1 (3.0 g) was subjected to silica gel CC (petroleum ether/EtOAc, 30:1-2:1) to yield **1** (8 mg). Fraction C was subjected to silica gel CC and eluted with

CHCl<sub>3</sub>/EtOAc (80:1-10:1) to give three fractions. The subfraction Fr.C2 was further applied to a silica gel CC (CHCl<sub>3</sub>/acetone, 100:1-10:1) to yield **2** (20 mg).

### **Bioactivity Assay for Delaying Paralysis in Transgenic Alzheimer Disease**

***Caenorhabditis elegans* Procedure:** The transgenic *Caenorhabditis elegans* strains CL2006 (unc-54/A $\beta$ 1-42), CL4176 (smg-1ts [myo-3/A $\beta$ 1-42 long 3'-untranslated region (UTR)]) is obtained from Caenorhabditis Genetics Center (CGC) (University of Minnesota, Minneapolis, MN). Worms were propagated at 16 °C on nematode growth medium (NGM) seeded with *E. coli* (OP50) as standard food resource. 100 eggs of CL4176 were added onto NGM containing tested compound at concentration of 100  $\mu$ M in 0.1% DMSO, and 0.1% DMSO was used as control group. The animals were kept at 16 °C till they are at their L3 larval stage, then transferred into a 25 °C incubator for 34 h. Paralysis worms were counted under a dissecting stereo microscope at 2 h intervals until all animals got into paralysis. A paralysis worm did not respond to any mechanical stimulus or only moved its head. The anti-AD bioactivity was described as the capacity of tested compound delaying worm paralysis. More worms are not paralysis, higher anti-AD bioactivity of the tested compounds have.

Fig. 1S <sup>1</sup>H NMR (400MHz, CDCl<sub>3</sub>) of compound 1




Fig. 2S  $^{13}\text{C}$  NMR and DEPT135 (100MHz,  $\text{CDCl}_3$ ) of compound **1**




Fig. 3S  $^1\text{H}$ - $^1\text{H}$  COSY spectrum of compound 1




Fig. 4S HSQC spectrum of compound 1







Fig. 5S HMBC spectrum of compound 1



**Fig. 6S** NOESY spectrum of compound **1**




Fig. 7S HR-ESI-MS spectrum of compound 1




Fig. 8S IR spectrum of compound 1




Fig. 9S <sup>1</sup>H NMR (400MHz, C<sub>5</sub>D<sub>5</sub>N) of compound 2




Fig. 10S  $^{13}\text{C}$  NMR and DEPT135 (100MHz,  $\text{C}_5\text{D}_5\text{N}$ ) of compound 2




Fig. 11S  $^1\text{H}$ - $^1\text{H}$  COSY spectrum of compound 2




Fig. 12S HSQC spectrum of compound 2






Fig. 13S HMBC spectrum of compound 2




Fig. 14S NOESY spectrum of compound 2




Fig. 15S HR-ESI-MS spectrum of compound 2




Fig. 16S IR spectrum of compound 2

